2010 Product Security Report

To amend the well-known saying about national defense, “Eternal vigilance is the price of pharmaceutical brand integrity.” But while there are various efforts to tighten supply chain security in pharma distribution, especially in selected countries outside the US, the industry […]

Read More

A Process-Based Approach To Aggregate Spend

Interactions between life sciences companies (pharma, biotech and med-device) and various healthcare providers (HCPs) and institutions (HCIs) over the past decade have been under increased scrutiny. The life sciences industry’s various interactions with HCPs/HCIs have led to: • Revisions to […]

Read More

Smoothing the Path to Drug Safety

The FDAA Act of 2007 empowered the FDA to require Risk Evaluation and Mitigation Strategies (REMS) for new and existing pharmaceutical products. After the first programs were introduced in 2008, REMS have now become an established part of the pharmaceutical […]

Read More

Defending Fair Market Value (FMV) Assessments

“Fair market value” is a legal term that tries to define the appropriateness of payments when there are conflicting or at least multiple justifications for those payments. FMV turns up in many business transactions, but specifically in payments occurring where […]

Read More

Medication adherence could get an EHR boost

Another year, another batch of studies lamenting the dismal performance of patients on extended medication therapy, such as chronic or longterm conditions. Most recently, the National Center for Patient Information and Education (NCPIE; Rockville, MD) paired up with Prescription Solutions, […]

Read More

Improving Outcomes Research Protocols

Today, the need to make better coverage and spending decisions throughout the healthcare arena is a universal goal. In addition to efforts throughout the pharma industry, there are also a number of government and academic initiatives under way to help […]

Read More